AGTR1 and chronic kidney disease: RAS blockade with Ang-converting enzyme inhibitors (ACEIs) or AT1 receptor (AT1R) blockers (ARBs) have been shown in landmark clinical trials to dramatically attenuate the decline in renal function associated with CKD [12–16].